Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Searching for Improved Flu Vaccines - The Time Is Now.

Atmar RL, Keitel WA.

J Infect Dis. 2019 Oct 30. pii: jiz545. doi: 10.1093/infdis/jiz545. [Epub ahead of print] No abstract available.

PMID:
31665360
2.

A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area.

Keitel WA, Potter GE, Diemert D, Bethony J, El Sahly HM, Kennedy JK, Patel SM, Plieskatt JL, Jones W, Deye G, Bottazzi ME, Hotez PJ, Atmar RL.

Vaccine. 2019 Oct 8;37(43):6500-6509. doi: 10.1016/j.vaccine.2019.08.075. Epub 2019 Sep 9.

PMID:
31515141
3.

Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.

Munoz FM, Anderson EJ, Bernstein DI, Harrison CJ, Pahud B, Anderson E, Creech CB, Berry AA, Kotloff KL, Walter EB, Atmar RL, Bellamy AR, Chang S, Keitel WA.

Vaccine. 2019 Aug 23;37(36):5161-5170. doi: 10.1016/j.vaccine.2019.07.085. Epub 2019 Jul 30.

PMID:
31375440
4.

Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.

Keitel WA, Voronca DC, Atmar RL, Paust S, Hill H, Wolff MC, Bellamy AR; VTEU H5N1 Vaccine Working Group.

Vaccine. 2019 Sep 3;37(37):5535-5543. doi: 10.1016/j.vaccine.2019.04.066. Epub 2019 May 31. Review.

PMID:
31160101
5.

Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

El Sahly HM, Atmar RL, Patel SM, Bellamy A, Liu L, Hong W, Zhu H, Guan Y, Keitel WA; DMID 13-0033 Vaccine Study Group.

Vaccine. 2019 May 1;37(19):2561-2568. doi: 10.1016/j.vaccine.2019.03.071. Epub 2019 Apr 4.

PMID:
30955980
6.

Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood.

El Sahly HM, Gorchakov R, Lai L, Natrajan MS, Patel SM, Atmar RL, Keitel WA, Hoft DF, Barrett J, Bailey J, Edupuganti S, Raabe V, Wu HM, Fairley J, Rouphael N, Murray KO, Mulligan MJ.

Open Forum Infect Dis. 2018 Dec 19;6(1):ofy352. doi: 10.1093/ofid/ofy352. eCollection 2019 Jan.

7.

Influenza Vaccines After 7 Decades: Still on the Learning Curve.

Keitel WA, Atmar RL.

J Infect Dis. 2019 Sep 13;220(8):1240-1242. doi: 10.1093/infdis/jiy724. No abstract available.

PMID:
30561693
8.

Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.

Munoz FM, Jackson LA, Swamy GK, Edwards KM, Frey SE, Stephens I, Ault K, Winokur P, Petrie CR, Wolff M, Patel SM, Keitel WA.

Vaccine. 2018 Dec 18;36(52):8054-8061. doi: 10.1016/j.vaccine.2018.10.088. Epub 2018 Nov 8.

PMID:
30416018
9.

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH.

Vaccine. 2018 Jan 29;36(5):606-614. doi: 10.1016/j.vaccine.2017.12.061. Epub 2017 Dec 24.

10.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB; DMID 08-0006 Tularemia Vaccine Study Group.

Vaccine. 2017 Aug 24;35(36):4730-4737. doi: 10.1016/j.vaccine.2017.07.024. Epub 2017 Jul 24.

11.

Challenges Remain for Influenza Vaccination of Children.

Edwards KM, Keitel WA.

J Infect Dis. 2016 Nov 15;214(10):1470-1472. Epub 2016 Aug 28. No abstract available.

PMID:
27571903
12.

Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.

Balderas MA, Nguyen CT, Terwilliger A, Keitel WA, Iniguez A, Torres R, Palacios F, Goulding CW, Maresso AW.

Infect Immun. 2016 Nov 18;84(12):3408-3422. Print 2016 Dec.

13.

Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.

Feldstein LR, Matrajt L, Elizabeth Halloran M, Keitel WA, Longini IM Jr; H5N1 Vaccine Working Group.

Vaccine. 2016 Jul 19;34(33):3796-802. doi: 10.1016/j.vaccine.2016.05.067. Epub 2016 Jun 20.

14.

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA.

Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4.

15.

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Clin Vaccine Immunol. 2015 Nov 11;23(1):73-7. doi: 10.1128/CVI.00475-15. Print 2016 Jan.

16.

Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?

Atmar RL, Keitel WA.

J Infect Dis. 2016 Apr 15;213(8):1211-3. doi: 10.1093/infdis/jiv459. Epub 2015 Oct 28. No abstract available.

PMID:
26516140
17.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR.

JAMA. 2015 Jul 21;314(3):237-46. doi: 10.1001/jama.2015.7916.

PMID:
26197184
18.

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.

Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL.

Open Forum Infect Dis. 2014 Oct 8;1(3):ofu091. doi: 10.1093/ofid/ofu091. eCollection 2014 Dec.

19.

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Winokur PL, Patel SM, Brady R, Chen WH, El-Kamary SS, Edwards K, Creech CB, Frey S, Keitel WA, Belshe R, Walter E, Bellamy A, Hill H.

J Infect Dis. 2015 Aug 15;212(4):525-30. doi: 10.1093/infdis/jiv087. Epub 2015 Feb 23.

20.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group.

J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3.

21.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.

22.

Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Pondo T, Rose CE Jr, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker S, Jacobson RM, Poland GA, McNeil MM.

Vaccine. 2014 Jun 12;32(28):3548-54. doi: 10.1016/j.vaccine.2014.04.025. Epub 2014 Apr 24.

23.

Influenza A(H5N1) vaccines: are we better prepared for the next pandemic?

Keitel WA, Piedra PA.

J Infect Dis. 2014 Jan 1;209(1):1-3. doi: 10.1093/infdis/jit573. Epub 2013 Oct 24. No abstract available.

PMID:
24158956
24.

Assessing agreement of repeated binary measurements with an application to the CDC's anthrax vaccine clinical trial.

Pan Y, Rose CE, Haber M, Ma Y, Carrasco JL, Stewart B, Keitel WA, Keyserling H, Jacobson RM, Poland G, McNeil MM.

Int J Biostat. 2013 Jul 27;9(1). pii: /j/ijb.2013.9.issue-1/ijb-2012-0001/ijb-2012-0001.xml. doi: 10.1515/ijb-2012-0001.

25.

Effects of infection and disease with Mycobacterium tuberculosis on serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen.

Keitel WA, Dai Z, Awe RW, Atmar RL, Morris S, Schneerson R, Robbins JB.

BMC Infect Dis. 2013 Jun 19;13:276. doi: 10.1186/1471-2334-13-276.

26.

Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).

Keitel WA, Piedra PA, Atmar RL, Demmler G, El Sahly HM, Barrett J, Halpin RA, Lagos R, Fisher-Hoch S, Munoz F.

BMC Res Notes. 2013 May 3;6:177. doi: 10.1186/1756-0500-6-177.

27.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group.

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30.

28.

Investigators' perspectives on translating human microbiome research into clinical practice.

Slashinski MJ, Whitney SN, Achenbaum LS, Keitel WA, McCurdy SA, McGuire AL.

Public Health Genomics. 2013;16(3):127-33. doi: 10.1159/000350308. Epub 2013 Apr 24.

29.

Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus).

Nofs SA, Atmar RL, Keitel WA, Hanlon C, Stanton JJ, Tan J, Flanagan JP, Howard L, Ling PD.

Vet Immunol Immunopathol. 2013 Jun 15;153(3-4):308-11. doi: 10.1016/j.vetimm.2013.03.008. Epub 2013 Mar 26.

PMID:
23582266
30.

Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.

Couch RB, Atmar RL, Keitel WA, Quarles JM, Wells J, Arden N, Niño D.

Vaccine. 2012 Dec 17;31(1):190-5. doi: 10.1016/j.vaccine.2012.10.065. Epub 2012 Oct 26.

31.

Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.

Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA.

J Infect Dis. 2012 Oct 1;206(7):1069-77. doi: 10.1093/infdis/jis402. Epub 2012 Aug 13.

32.

Perspectives on human microbiome research ethics.

McGuire AL, Achenbaum LS, Whitney SN, Slashinski MJ, Versalovic J, Keitel WA, McCurdy SA.

J Empir Res Hum Res Ethics. 2012 Jul;7(3):1-14. doi: 10.1525/jer.2012.7.3.1.

33.

Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial.

Stewart B, Rose CE, Tokars JI, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker SD, Jacobson RM, Poland GA, McNeil MM.

Vaccine. 2012 Aug 31;30(40):5875-9. doi: 10.1016/j.vaccine.2012.06.076. Epub 2012 Jul 17.

34.

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.

El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA.

J Infect Dis. 2012 Mar 1;205(5):703-12. doi: 10.1093/infdis/jir837. Epub 2012 Jan 24.

35.

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine.

Atmar RL, Keitel WA, Quarles JM, Cate TR, Patel SM, Nino D, Wells J, Arden N, Guo K, Hill H, Couch RB.

Vaccine. 2011 Oct 19;29(45):8066-72. doi: 10.1016/j.vaccine.2011.08.044. Epub 2011 Aug 22.

36.

Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.

Jackson LA, Patel SM, Swamy GK, Frey SE, Creech CB, Munoz FM, Artal R, Keitel WA, Noah DL, Petrie CR, Wolff M, Edwards KM.

J Infect Dis. 2011 Sep 15;204(6):854-63. doi: 10.1093/infdis/jir440.

37.

Safety and immunogenicity of a candidate parvovirus B19 vaccine.

Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W.

Vaccine. 2011 Oct 6;29(43):7357-63. doi: 10.1016/j.vaccine.2011.07.080. Epub 2011 Jul 30.

38.

Intanza(®): a new intradermal vaccine for seasonal influenza.

Atmar RL, Patel SM, Keitel WA.

Expert Rev Vaccines. 2010 Dec;9(12):1399-409. doi: 10.1586/erv.10.134. Review.

PMID:
21105776
39.

Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic.

El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Sim BK, Long C, Keitel WA.

Clin Vaccine Immunol. 2010 Oct;17(10):1552-9. doi: 10.1128/CVI.00082-10. Epub 2010 Aug 11.

40.

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.

Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA.

Vaccine. 2010 Apr 9;28(17):3025-9. doi: 10.1016/j.vaccine.2009.10.152. Epub 2009 Nov 18.

41.

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.

Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM.

Vaccine. 2009 Dec 11;28(2):379-85. doi: 10.1016/j.vaccine.2009.10.037. Epub 2009 Oct 29.

PMID:
19879222
42.

Antibody quantity versus quality after influenza vaccination.

Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, James JA, Thompson LF, Air GM.

Vaccine. 2009 Oct 23;27(45):6358-62. doi: 10.1016/j.vaccine.2009.06.090.

43.

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H.

Vaccine. 2009 Nov 5;27(47):6642-8. doi: 10.1016/j.vaccine.2009.03.015. Epub 2009 Mar 25.

44.

Vaccines for pandemic influenza: summary of recent clinical trials.

Keitel WA, Atmar RL.

Curr Top Microbiol Immunol. 2009;333:431-51. doi: 10.1007/978-3-540-92165-3_21. Review.

PMID:
19768418
45.

Adjuvants for pandemic influenza vaccines.

Atmar RL, Keitel WA.

Curr Top Microbiol Immunol. 2009;333:323-44. doi: 10.1007/978-3-540-92165-3_16. Review.

PMID:
19768413
46.

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Couch RB, Atmar RL, Cate TR, Quarles JM, Keitel WA, Arden NH, Wells J, Niño D, Wyde PR.

Vaccine. 2009 Aug 27;27(39):5344-8. doi: 10.1016/j.vaccine.2009.06.084. Epub 2009 Jul 14.

47.

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.

Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H.

Vaccine. 2009 Aug 13;27(37):5091-5. doi: 10.1016/j.vaccine.2009.06.057. Epub 2009 Jul 3.

48.

Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.

El Sahly HM, Atmar RL, Patel SM, Wells JM, Cate T, Ho M, Guo K, Pasetti MF, Lewis DE, Sztein MB, Keitel WA.

Vaccine. 2009 Aug 6;27(36):4905-11. doi: 10.1016/j.vaccine.2009.06.036. Epub 2009 Jun 28.

49.

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA.

Hum Vaccin. 2009 Aug;5(8):536-44. Epub 2009 Aug 14.

50.

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.

Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium.

Arch Intern Med. 2008 Dec 8;168(22):2405-14. doi: 10.1001/archinternmed.2008.513.

PMID:
19064822

Supplemental Content

Loading ...
Support Center